<SEC-DOCUMENT>0001144204-16-083530.txt : 20160222
<SEC-HEADER>0001144204-16-083530.hdr.sgml : 20160222
<ACCEPTANCE-DATETIME>20160222083018
ACCESSION NUMBER:		0001144204-16-083530
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160222
FILED AS OF DATE:		20160222
DATE AS OF CHANGE:		20160222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36000
		FILM NUMBER:		161443659

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v432399_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of February, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <B>000-36000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>XTL Biopharmaceuticals Ltd.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5 HaCharoshet St.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Raanana 4365603</B><BR>
<B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Israel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Incorporation by Reference: This Form 6-K of XTL Biopharmaceuticals
Ltd. is hereby incorporated by reference into the registration statements on Form S-8 (File No. 333-148085, File No. 333-148754
and File No. 333-154795) and Form F-3 (File No. 333-194338).</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="text-transform: uppercase"><IMG SRC="image_001.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>XTL
Biopharmaceuticals receives European medicines agency&rsquo;s sme status </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><B><I>SME status supports XTL&rsquo;s
European clinical program for hCDR1 in the treatment of lupus and its upcoming Phase 2 trial</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>RAANANA,
Israel</B></FONT><B> - (February 22, 2016) &ndash; <FONT STYLE="color: Blue"><U>XTL Biopharmaceuticals Ltd.</U></FONT> (NASDAQ:
XTLB, TASE: XTLB.TA) </B>(&ldquo;XTL&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage biopharmaceutical company developing
its lead product for the treatment of lupus, today announced that the European Medicines Agency (EMA) has granted the Company
Small or Medium Sized Business Enterprise (SME) status in Europe. This comes in advance of XTL&rsquo;s global Phase 2 trial of
its lead compound hCDR1 for the treatment of lupus, which is expected to commence in 2016 in markets including the U.S. and Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SME status offers biopharmaceutical companies
numerous benefits for medicinal products going through clinical testing and marketing approval processes in Europe. Incentives
include: fee reductions and exemptions in pre- and post-marketing authorization phases; administrative, procedural and scientific
advice, and eligibility for funding and grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We believe SME status will benefit our hCDR1 clinical
program in Europe during our Phase 2 trial and leading up to marketing registration. We look forward to a continued productive
relationship with the EMA,&rdquo; stated Josh Levine, Chief Executive Officer of XTL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About hCDR1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">hCDR1 is a novel compound with a unique mechanism of action
and with clinical data on over 400 patients in three clinical studies. The drug has a favorable safety profile, is well tolerated
by patients and has demonstrated efficacy in at least one and possibly more clinically meaningful endpoints. For more information
please see a peer reviewed article in Lupus Science and Medicine journal (<FONT STYLE="color: Blue"><U>http://lupus.bmj.com/content/2/1/e000104.full</U></FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About Systemic Lupus Erythematosus (SLE)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lupus is a chronic autoimmune disease involving
many systems in the human body, including joints, kidneys, central nervous system, heart, hematological system and others. The
biologic basis of the disease is a defect in the immune (defense) system, leading to production of self (auto) antibodies, attacking
the normal organs and causing irreversible damage. According to the Lupus Foundation of America, at least 1.5 million Americans
have the disease (more than 5 million worldwide) with more than 16,000 new cases diagnosed each year. The majority of patients
are women of childbearing years. There has been only one drug approved by the FDA in the last 50 years and recently two of the
few drugs in advanced development did not meet their primary endpoints in Phase 3 trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XTL Biopharmaceuticals Ltd.</FONT></TD>
    <TD STYLE="width: 7%; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 Hacharoshet Street, Raanana, 43656, Israel</FONT></TD>
    <TD STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +972 9 955 7080; email: <FONT STYLE="color: blue"><U>ir@xtlbio.com</U></FONT> </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About XTL Biopharmaceuticals Ltd.
(XTL)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL Biopharmaceuticals Ltd., is a clinical-stage
biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus.
The Company's lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE).
There currently is no effective treatment on the market for SLE. hCDR1 has robust clinical data in three clinical trials with 400
patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals. Based on safety
and efficacy data shown in a completed Phase 2 study, the Company expects to initiate a Phase 2 trial in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">XTL is traded on the Nasdaq Capital Market
(XTLB) and the Tel Aviv Stock Exchange (XTLB.TA). XTL shares are included in the following indices: Tel-Aviv Biomed, Tel-Aviv MidCap,
and Tel-Aviv Tech Index</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>For further information, please contact:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Relations, XTL Biopharmaceuticals
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: <FONT STYLE="color: Blue"><U>ir@xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Blue"><U>www.xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">===============================================================</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Cautionary Statement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain forward-looking
statements, about XTL&rsquo;s expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as &quot;believe,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;may,&quot;
&quot;should&quot; or &quot;anticipate&quot; or their negatives or other variations of these words or other comparable words or
by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases
or oral statements made by or with the approval of one of XTL&rsquo;s authorized executive officers. Forward-looking statements
relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause
XTL&rsquo;s actual results to differ materially from any future results expressed or implied by the forward-looking statements.
Many factors could cause XTL&rsquo;s actual activities or results to differ materially from the activities and results anticipated
in such forward-looking statements, including, but not limited to, the factors summarized in XTL&rsquo;s filings with the SEC and
in its periodic filings with the TASE. In addition, XTL operates in an industry sector where securities values are highly volatile
and may be influenced by economic and other factors beyond its control. XTL does not undertake any obligation to publicly update
these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors
associated with an investment in our ADSs or ordinary shares which are included in our Registration Statement on Form F-1 as filed
with the U.S. Securities and Exchange Commission on December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%; font-size: 10pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XTL Biopharmaceuticals Ltd.</FONT></TD>
    <TD STYLE="width: 7%; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5 Hacharoshet Street, Raanana, 43656, Israel</FONT></TD>
    <TD STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Page 2</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tel: +972 9 955 7080; email: <FONT STYLE="color: blue"><U>ir@xtlbio.com</U></FONT> </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 50%; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>XTL BIOPHARMACEUTICALS LTD.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: February 22, 2016</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: <U>/s/ Josh Levine</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 0 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh Levine</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 0 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- /\# 2(  A$! Q$!_\0
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M:0K9NZ*6_>,G7VJ3P==7L^FL+QG?#_(S]<5)XKOCI]@)D178L!AJE\+W9O\
M31.R*K9QA:MN7U7X5:^_4S2C];^)WMMT-VBL[5M:L]'AWW#_ #'[J+U-<9=^
M.]0DD/V2*.)>P8;C44<)5K*\5H:5\91HNTGKV/1**\SB\;:Q&P\PQ.N>04P:
MZK1/%MKJCB"9?(N#T4GAOH:NK@*U)<S5UY$4<?0JRY4[/S.BHHHKC.T****
M*=]9QW,+*R@@CD&OG#Q=:Z=9^(KF'39-\0;YP/NJW<"O3/B5X^^P1R:+I4H-
MRXQ/*I_U8]![UXOR3W9B?Q)KVLMP\XKVDM$^GZGDX^M&7[M= KU'X4Z7IET9
M;GS!)?J<,C=47VK@M1\/ZAI=E!=W,)6.89]U^M0Z/J]YH>I17]C*4E0\CLP]
M#797A]8HM4Y?UV.6C+V%5.:/J:*-8T  I]87A7Q/:>*-)2[MR%E'$L1/*-_A
M6[7S<HN#<9;H]^,E)76P5D^)?^1?O?\ KBU:U9/B7_D7[W_KBU$/B02V9\O-
MU;ZFO=OA'_R*0_Z[-7A+=6^IKW;X1_\ (I#_ *[-7NYG_ ^:/&R_^+\CT&N,
M^)O_ ")UW^%=G7&?$W_D3KO\*\7#_P 6/JCUJW\.7HSYZ_A%?2O@;_D4--_Z
MXBOFK^$5]*^!O^10TW_KB*]?-?@CZ_H>9EOQR]#HZ***\,]<*\]\=_\ 'Y;_
M $->A5Y[X[_X_+?Z&NW+_P#>(_/\CAS'_=I?+\S'T71WU.4L0?*4X..YKN+;
MPY#'& (U''I2>$K6--(@D &67)/K71TL9B)U:K3>BZ#P6&A2I)I:OJ<=J?A:
M*2,E4"MV9:Y.RN[G0-7# D%&PZ]F%>MNH92"*\U\90K%JB%1@E.:WR^M*4G1
MGK%HY\QHQC%5X:23-CQE.MQH\,J'*N014GA2Y6T\.R3N?ECRQK%U%R_@^RW'
M)X_G1#(T?@N4+GE\'Z5?LO\ 9U3_ +]OQ(]K;$.I_<O^!ESS7.O:LSDEGD/R
MCLJUUVF^%HHX@60,W=C61X)MTFO9V89*J,5Z,JA5 %1F%:2G[&.D4:9=0BX>
MVGK)G-7/AF"2,@QJ>/2N+U?29-*N%="P0GY6[J:]:KF?%]M&VDRN<#&"#[UA
M@\1.G42OH^AOC<-"I2<K:K6Y8\*ZPVJ:8/-.9XOE;W]ZWJ\^\!.1>72YXV*<
M?C7H-3C*:IUY1CL7@JCJ4(REO_D%<#\1/'2>'[5M.L'#:C,O4<^4/4^];?C+
MQ!<Z%I):QM9+B\ERL2JN0ON:^?KJPUF\NY;FZM;B2>5BSLR]36V!PT9OGJ/1
M?B1BZ\H+D@M3.DD>61Y97+R.<LS'))KT;X?>"6NI4U2_B.WK#&PZ_P"T:H>"
M?!%QJ5\+K48&CMXF^6-A]\_X5[I96:6L*JJ@ #  [5TX_&67LJ;]7^ASX/"W
M?M*GR,O5/#]M?:;);31AHW7!%> ^)_#EQX<U%H7!:W<YBD]1Z'WKZ<(R,&N;
M\3^'+;6M/DMYDRK#((ZJ?6N'"8IT):[/<[,3AU6CYG@?ASQ%>>&=62^M&R.D
MD9/#KZ5]&Z#KMEXATN.^LI R,,,O=&[@U\Z:GX8U33+^2U:UDD"GY709!%:_
M@[4=>\+ZJLT5C<26LAQ-"!P1ZCWKTL91IUX\\&K_ )G!A:M2C+DFG;\CZ'K)
M\2_\B_>_]<6K0M+E;NUBN$!"R*& 88(JAXB1I-"O$0%F,3  =Z\2.DD>M+6+
M/EUNK?4U[M\(_P#D4A_UV:O%VT;4PS#[#-G)_AKVWX5VT]KX6$=Q$T;^:QVL
M,'%>WF4XNCH^J/)P$9*KJNAWE<9\3?\ D3KO\*[.N0^(]O+<^$[J.&-I'.,*
MHYKQZ&E6/JCU*W\.7H?.P^Z*]D\-?$O0-)\/V=E<?:/.AC"MM3(S7E(T;4P
M#8S?]\T?V/J7_/C-_P!\U]#7IT:Z2F]O,\.C.K1;<5^![;_PMWPUZW/_ '[_
M /KT?\+=\->MS_W[_P#KUXE_8^I?\^,W_?-']CZE_P ^,W_?-<WU#"]_Q.CZ
MYB.WX'MO_"W?#7K<_P#?O_Z]9^KZS9>*]-&HZ:)#' Y5]ZX->1?V/J7_ #XS
M?]\UZK\,M+G&@WD-U T>Z4X5QC(K.I1HX9*K3=VGW*C4JXF]*HK)KL;G@K6X
MD3^S[APK9S&2>"/2NYKR[5?#MQ:3,]N"R9R!W%16_B'6[)?*6>0@<8==V*BI
MA88E^TH26NZ8J6*J85>RKQ>FS1ZC<W,-K TL\BHBC))->5:O?/K>LEXE.UCL
MC'M3)[C5=9D E>67_9/"C\*ZCP[X<^SL)Y@&E_04X1IX).<G>?1"G*ICFH15
MH=65/$-M]D\/6\0Z*0*72+3[9X6EBQR<X^M7_&L+?V8BHI.&'05-X.A)T;8Z
MD$L>"*QYVL&I7UYKFO(GC'&VG+8Y'0=2.BZMNF!\LG9(/3WKU2">.YA66)PZ
M,,@@UQ'B'PV99&G@ $G?T:N=M[S5M'8I$\L0_N]16TX4\:E.#M/JF8TZE3 M
MPG&\.C1ZZ3@9/2N#\::W%,!I]NX?!S(PZ#VK#N->UJ]3RGGEP>R#&:GTGP[/
M=S*]PI5,YVGJ:*6%IX9^UK26FR0ZN*J8I>RH1>N[9M^"+%HXI+EACS#@?2NV
MJI8VBVL"HH  & *MUYM:JZM1S?4].A25*FH+H03VXF&#53^R(2<X%:5%9&I6
M@LXX/N@59HHH *0@$8-+10!1ETR&5LE134TJ*-L@"M"B@!J)L7%)(@D7::?1
M0!G-I,3-NP/RJW!;K N%%344 %130K,N#4M% &:=(A)S@4G]CP^@K3HH S/[
M'A]!1_8\/H*TZ* ,S^QX?05<@M4@&%%3T4 036L<P^8"J+Z+$QR *U:* ,Z'
M288SG J^D:QC"C%.HH @N+99QS2P6ZP+A:FHH 9)$L@PPS5"72(9"3@5I44
792:+$IR0*O0VL<(^4"IZ* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
